echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Application of Dominant Fragment Hybridization Strategy in Drug Development

    Application of Dominant Fragment Hybridization Strategy in Drug Development

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hybridization strategy for dominant fragments

    It is a classic drug design method.


    01

    Development of LSD1 inhibitors

    Trans-2-Phenylcyclopropylamine (PCPA) has strong inhibitory activity on monoamine oxidase (MAOs) and can be used to treat depression.


    02

    Development of Mcl-1 inhibitors

    Myeloid leukemia factor-1 is highly expressed in a variety of tumor cells, and has a promoting effect on the abnormal proliferation of tumor cells.


    03

    Development of NMT inhibitors

    Derivatives 6 and 7 obtained through high-throughput screening have strong inhibitory activity on N-myristoyltransferase (NMT).


    04

    Research and development of anti-HIV-1 drugs

    Researchers comparatively analyzed the docking results of derivatives 9 and 10 with HIV-1 non-nucleoside reverse transcriptase and found that carbamate groups are one of the key factors for high-efficiency anti-drug resistance, and derivatives 9 and HIV-1 The X-ray crystal complex of non-nucleoside reverse transcriptase showed that 3,5-dichlorophenyl and amino acid residues can interact through hydrogen bonds.


    Later, through molecular docking and hybridization strategies of dominant fragments, other researchers discovered that new pyridine amide and pyridone derivatives have strong inhibitory activity against HIV.


    The hybridization strategy based on dominant fragments has the advantages of clear thinking, short development time and low cost in drug design.


    references

    [1] Ueda R, Suzuki T, Mino K, et al.


    [2] Pelz NF, Bian ZG, Zhao B, et al.


    [3] Hutton JA.


    [4] Liu ZQ, Chen WM, Zhan P, etal.


    [5] Chen WM, Zhan P, Rai D, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.